Render Target: SSR
Render Timestamp: 2024-11-14T22:47:01.899Z
Commit: 3c1f305a63297e594ac8d7bb5424007d592d68be
XML generation date: 2024-09-30 01:57:27.979
Product last modified at: 2024-09-30T08:02:07.158Z
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

Granzyme M (E7B4W) Rabbit mAb #37765

Filter:
  • WB

    Supporting Data

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa) 25-30
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    Granzyme M (E7B4W) Rabbit mAb recognizes endogenous levels of total Granzyme M protein. This antibody does not cross-react with human Granzyme A, B, H, or K proteins.

    Species Reactivity:

    Human

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ala141 of human Granzyme M protein.

    Background

    Granzymes are a family of serine proteases expressed by cytotoxic T lymphocytes and natural killer (NK) cells and are key components of immune responses to pathogens and transformed cells (1). Granzymes are synthesized as zymogens and are processed into mature enzymes by cleavage of a leader sequence. They are released by exocytosis in lysosome-like granules containing perforin, a membrane pore-forming protein. Granzyme B has the strongest apoptotic activity of all the granzymes as a result of its caspase-like ability to cleave substrates at aspartic acid residues thereby activating procaspases directly and cleaving downstream caspase substrates (2,3).
    Granzyme M prefers to cleave after a Methionine or Leucine residue, and proteolyzes a restricted set of macromolecular substrates (4-7). Granzyme M is highly expressed in NK, NKT, γδ T cells, and in differentiated effector CD8+ T cells, suggesting a role for Granzyme M in both innate and adaptive immunity (4-11). After perforin-mediated entry into a target cell, various reports show Granzyme M can induce apoptosis and tumor cell death, stimulate LPS-mediated inflammation, or inhibit viral replication (4,11-15).
    1. Trapani, J.A. (2001) Genome Biol. 2, REVIEWS 3014.
    2. Lord, S.J. et al. (2003) Immunol. Rev. 193, 31-8.
    3. Trapani, J.A. and Sutton, V.R. (2003) Curr. Opin. Immunol. 15, 533-43.
    4. de Poot, S.A. and Bovenschen, N. (2014) Cell Death Differ 21, 359-68.
    5. Smyth, M.J. et al. (1993) J Immunol 151, 6195-205.
    6. Kelly, J.M. et al. (1996) Immunogenetics 44, 340-50.
    7. Mahrus, S. et al. (2004) J Biol Chem 279, 54275-82.
    8. Smyth, M.J. et al. (1995) Immunogenetics 42, 101-11.
    9. de Koning, P.J. et al. (2010) Mol Immunol 47, 903-11.
    10. Bade, B. et al. (2005) Int Immunol 17, 1419-28.
    11. van Domselaar, R. et al. (2013) Cell Death Differ 20, 419-29.
    12. Lu, H. et al. (2006) J Immunol 177, 1171-8.
    13. de Poot, S.A. et al. (2014) Cell Death Differ 21, 416-26.
    14. van Domselaar, R. et al. (2010) J Immunol 185, 7605-13.
    15. Anthony, D.A. et al. (2010) J Immunol 185, 1794-803.
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.